Skip to content
Strategic Partnering
News
Contact Us
Menu
Strategic Partnering
News
Contact Us
Invest
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Menu
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Strategic Partnering
Contact Us
Menu
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Strategic Partnering
Contact Us
Positive Topline Data from Phase 2 Study of FS2 for Treatment of Keloid Scars
01-21-2021-BirchBioMed-FS2-trial-results_FINAL